Vectura Group PLC (VEC) Receives GBX 211.29 Average PT from Brokerages
Shares of Vectura Group PLC (LON:VEC) have been given an average rating of “Buy” by the ten analysts that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and seven have given a buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is GBX 211.29 ($2.74).
A number of analysts recently commented on VEC shares. N+1 Singer reissued a “hold” rating on shares of Vectura Group PLC in a research report on Thursday, June 29th. Numis Securities Ltd reissued a “buy” rating and set a GBX 225 ($2.92) price objective on shares of Vectura Group PLC in a research report on Friday, May 5th. Peel Hunt reissued a “hold” rating and set a GBX 160 ($2.08) price objective on shares of Vectura Group PLC in a research report on Thursday, June 29th. Shore Capital reissued a “buy” rating on shares of Vectura Group PLC in a research report on Wednesday, August 16th. Finally, J P Morgan Chase & Co lowered their price objective on Vectura Group PLC from GBX 240 ($3.12) to GBX 210 ($2.73) and set an “overweight” rating for the company in a research report on Friday, May 12th.
Vectura Group PLC (LON:VEC) traded up 0.36% during trading on Tuesday, hitting GBX 111.00. The stock had a trading volume of 1,148,753 shares. The stock’s 50 day moving average price is GBX 112.36 and its 200 day moving average price is GBX 130.17. Vectura Group PLC has a 12-month low of GBX 107.60 and a 12-month high of GBX 166.97. The firm’s market cap is GBX 754.07 million.
Vectura Group PLC Company Profile
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.